RxDoctor Payments Data

Chun Chen

Family · Monterey Park, CANPI 1326704354

Payments from drug & device makers

$9,512in general payments, 2019–2025

Across 414 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$930
  • GSK$913
  • Bayer$870
  • AstraZeneca$637
  • Boehringer Ingelheim$487
  • Ardelyx, Inc.$481
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$9,512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,512 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$2,866
Medicare patients
19
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase45$95,887
VascepaIcosapent Ethyl238$92,678
EliquisApixaban104$75,872
Dupixent PenDupilumab17$60,916
LinzessLinaclotide101$60,091
JardianceEmpagliflozin76$52,278
FarxigaDapagliflozin Propanediol77$50,589
OzempicSemaglutide49$50,423
ProliaDenosumab29$47,795
KerendiaFinerenone59$43,722
JanuviaSitagliptin Phosphate64$41,085
RybelsusSemaglutide35$30,286
MounjaroTirzepatide29$29,585
Xigduo XrDapaglifloz Propaned/Metformin50$28,994
Synjardy XrEmpagliflozin/Metformin Hcl30$28,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$442$181,584183 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta$487$104,043140 claims
Novo NordiskOzempic, Rybelsus$190$80,70884 claims
PfizerEliquis$180$75,872104 claims
AstraZenecaFarxiga, Breztri Aerosphere$637$71,143106 claims
MerckJanuvia, Janumet, Janumet Xr$291$67,434109 claims
Lilly USA, LLCMounjaro, Trulicity$358$52,66648 claims
AmgenProlia$930$47,79529 claims
BayerKerendia$870$43,72259 claims
GileadVemlidy$49$22,43316 claims
Phathom Pharmaceuticals, Inc.Voquezna$462$20,06126 claims
GSKTrelegy Ellipta$913$19,86930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →